Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010970 | 0.80 | PGAM1 (0.42) | L3MBTL1PGAM1 | |
| SCHEMBL22010821 | 0.77 | RARB (0.36) | MAPTRAB9ARARB | |
| SCHEMBL29118536 | 0.76 | PGAM1 (0.42) | L3MBTL1PGAM1 | |
| SCHEMBL22010979 | 0.74 | — | — | |
| SCHEMBL22011189 | 0.73 | RARB (0.37) | MAPTRAB9AL3MBTL1RARBGPR55 | |
| SCHEMBL9548148 | 0.73 | RARB (0.45) | MAPTRAB9AL3MBTL1RARB | |
| SCHEMBL9406337 | 0.73 | RARB (0.45) | MAPTRAB9AL3MBTL1RARB | |
| SCHEMBL22010955 | 0.73 | RARB (0.40) | MAPTRAB9AL3MBTL1RARBGPR55 | |
| SCHEMBL22010835 | 0.72 | RARB (0.40) | MAPTRAB9AL3MBTL1RARBGPR55 | |
| SCHEMBL22010998 | 0.71 | RARB (0.44) | MAPTRAB9AL3MBTL1RARBGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | MAPT 1234/4885RAB9A 2387/4885L3MBTL1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.